Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Fresenius SE & Co. KGaA sell Sievi

Start price
€17.17
31.05.10 / 50%
Target price
€10.00
30.11.10
Performance (%)
29.94%
End price
€22.31
30.11.10
Summary
This prediction ended on 30.11.10 with a price of €22.31. The prediction closed with a disappointing performance of 29.94%. Sievi has 50% into this prediction

Fresenius is a German healthcare company listed on the Frankfurt and New York stock exchanges under the symbol FSNUF. The company is primarily engaged in the production and distribution of medical devices, pharmaceuticals, and services related to renal dialysis, critical care, and hospital operations. With over 290,000 employees and operations in more than 100 countries, Fresenius is one of the largest healthcare providers in the world. The company has experienced steady growth over the years, driven by its innovative product portfolio, strategic acquisitions, and a focus on operational efficiency.

Performance without dividends (%)
Name 1w 1m 1y 3y
Fresenius SE & Co. KGaA 3.862% 3.862% 10.789% -30.996%
iShares Core DAX® 0.000% -2.064% 13.111% 16.685%
iShares Nasdaq 100 0.626% -2.884% 37.744% 43.441%
iShares Nikkei 225® 1.568% -5.892% 19.592% 4.617%
iShares S&P 500 0.334% -2.281% 27.745% 41.046%

Comments by Sievi for this prediction

In the thread Fresenius SE & Co. KGaA diskutieren
Prediction Sell
Perf. (%) 29.94%
Target price 10.000
Change
Ends at 30.11.10

Korrektur zu erwarten!

Auch Fresenius wird sich als Blue Chip dem allgemeinen Abwärtstrend an den Börsen nicht entziehen können. Nach einer fulminanten Erholung der Aktienmärkte vom Kursrutsch Ende 2008 / Anfang 2009 dürfte in Kürze die nächste Abwärtswelle einsetzen.

Prediction Sell
Perf. (%) 29.94%
Target price 10.000
Change
Ends at 30.11.10

(Laufzeit überschritten)

News

Fresenius: Gesundes Wachstum
Fresenius: Gesundes Wachstum
Eine gute Positionierung auf dem Gesundheitsmarkt und eine solide Nachfrage haben Fresenius im Geschäftsjahr 2011 einen währungsbereinigten Anstieg des Konzernergebnisses um 17% auf 770 Millionen